The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
复制标题
DOI：
10.1111/bjh.14477
复制
发表时间：
2017-03
影响因子：
6.5
通讯作者：
Oki Y
中科院分区：
文献类型：
--
作者：
Chihara D;Fanale MA;Miranda RN;Noorani M;Westin JR;Nastoupil LJ;Hagemeister FB;Fayad LE;Romaguera JE;Samaniego F;Turturro F;Lee HJ;Neelapu SS;Rodriguez MA;Wang M;Fowler NH;Davis RE;Medeiros LJ;Hosing C;Nieto YL;Oki Y
非特异性外周t细胞淋巴瘤（PTCL-NOS）和血管免疫母细胞t细胞淋巴瘤（AITL）患者经历疾病进展/复发的生存结果仍然很差。本文分析了1999 - 2015年间新诊断为PTCL-NOS （n=180）或AITL （n=141）的321例患者。从第一次疾病进展（FFS1, OS1）、第二次疾病进展（FFS2, OS2）和第三次疾病进展（FFS3, OS3）开始计算无故障生存期（FFS）和总生存期（OS）。中位随访时间为52个月，240例患者（135例PTCL-NOS， 105例AITL）出现进展/复发。PTCL-NOS患者FFS1、FFS2和FFS3的中位持续时间分别为3.1、2.5和2.1个月。AITL患者分别为5.5、2.9和2.3个月。在此期间（1999-2004-2005-2009和2010-2015），FFS1和OS1的复发时间没有改善。准氨蝶呤和罗咪地辛治疗后的中位FFS分别仅为3.0和2.5个月。挽救性自体和同种异体移植后的5年总生存率分别为32%和52%；而未接受移植的患者的5年生存率为10%。需要进一步研究更有效、更安全的新型治疗方法。
Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n=180) or AITL (n=141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3). With a median follow-up duration of 52 months, 240 patients (135 PTCL-NOS, 105 AITL) experienced progression/relapse. In patients with PTCL-NOS, the median durations of FFS1, FFS2 and FFS3 were 3.1, 2.5 and 2.1 months, respectively. In patients with AITL, they were 5.5, 2.9 and 2.3 months, respectively. There was no improvement in FFS1 and OS1 by the time of recurrence during this period (1999–2004–2005–2009 and 2010–2015). The median FFS after pralatrexate and romidepsin was only 3.0 and 2.5 months, respectively. The 5-year OS rates after salvage autologous and allogeneic transplant were 32% and 52%, respectively; while the 5-year OS rates for patients who did not undergo transplant was 10%. Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed.
登录
查看更多内容
罗米地辛治疗复发/难治性外周 T 细胞淋巴瘤：关键研究更新表明持久反应。
影响因子：
28.5
作者：
Coiffier B;Pro B;Prince HM;Foss F;Sokol L;Greenwood M;Caballero D;Morschhauser F;Wilhelm M;Pinter-Brown L;Padmanabhan Iyer S;Shustov A;Nielsen T;Nichols J;Wolfson J;Balser B;Horwitz S
通讯作者：
Horwitz S
影响因子：
6.5
作者：
Shustov AR;Gooley TA;Sandmaier BM;Shizuru J;Sorror ML;Sahebi F;McSweeney P;Niederwieser D;Bruno B;Storb R;Maloney DG
通讯作者：
Maloney DG
日本和美国血液学恶性肿瘤的发病率和趋势差异。
影响因子：
6.5
作者：
Chihara D;Ito H;Matsuda T;Shibata A;Katsumi A;Nakamura S;Tomotaka S;Morton LM;Weisenburger DD;Matsuo K
通讯作者：
Matsuo K
影响因子：
45.3
作者：
Vose, Julie M.;Neumann, M.;Harris, Mildred E.
通讯作者：
Harris, Mildred E.
影响因子：
45.3
作者：
Mak, Vivien;Hamm, Jeremey;Savage, Kerry J.
通讯作者：
Savage, Kerry J.